X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of $0.45, $0.46 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $15.27 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.